Clinical significance of anti-Ro and Anti-La antibodies: The role of isolated anti-La

Abstract

Objectives

The aim of the present study was to describe demographic, clinical, and immunological characteristics of SLE patients with anti-La/SSB antibodies positive versus anti-La/SSB negative patients.

Methods

Retrospective cross-sectional study, including all patients with SLE (≥4 ACR-1997 criteria) recruited in RELESSER registry. Sociodemographic, clinical, serological and comorbidities variables were collected. Anti-Ro-/La + patients were compared with the rest of the patients.

Results

In a study involving 4219 systemic lupus erythematosus (SLE) patients, 44/3893 (1.1%) were found to be positive for isolated anti-La/SSB antibodies. The mean age was 33.77 years, with a majority being female (88.6%) and Caucasian (90.5%). The most frequent comorbidities were smoking (48.8%), dyslipidemia (47.7%), and arterial hypertension (31.8%). Photosensitivity and mucosal ulcers were more common in anti-Ro+/La + patients compared to anti-Ro+/La- and anti-Ro-/La- patients. Anti-Ro+/La + patients had a lower frequency of lupus nephritis compared to anti-Ro+/La- patients. A multivariable regression model, considering various confounding factors, was applied to compare anti-La/SSB positive patients with negative ones. Isolated anti-La/SSB positive patients showed a lower occurrence of lupus nephritis and a higher frequency of cardiac manifestations.

Conclusions

The study suggests that patients with isolated anti-La/SSB antibodies may have a unique clinical profile, with a potential protective effect against lupus nephritis but an increased likelihood of cardiac manifestations.

Keywords

systemic lupus erythematosus antibodies lupic nephritis

Get full access to this article

View all access options for this article.

References

Cozzani

Drosera

Gasparini

, et al. Serology of lupus erythematosus: correlation between Immunopathological features and clinical Aspects. Autoimmune Dis 2014; 2014: 1–13.

Rekvig

. The dsDNA, anti-dsDNA antibody, and lupus nephritis: what we agree on, what must be done, and what the best strategy forward could be. Front Immunol 2019; 10: 1–17.

Hernández-Molina

Leal-Alegre

Michel-Peregrina

. The meaning of anti-Ro and anti-La antibodies in primary Sjögren’s syndrome. Autoimmun Rev 2011; 10: 123–125.

Fukuda

de Almeida

, et al. Anti-Ro antibody and cutaneous vasculitis in systemic lupus erythematosus. Clin Rheumatol 2009; 28: 301–304.

Wasicek

Reichlin

. Clinical and serological differences between systemic lupus erythematosus patients with antibodies to Ro versus patients with antibodies to Ro and La. J Clin Investig 1982; 69: 835–843.

Maddison

Isenberg

Goulding

, et al. Anti-La (SSB) identifies a distinctive subgroup of systemic lupus erythematosus. Rheumatology 1988; 27: 27–31.

Novak

Marques

Balbi

, et al. Anti-Ro/SSA and anti-La/SSB antibodies: association with mild lupus manifestations in 645 childhood-onset systemic lupus erythematosus. Autoimmun Rev 2017; 16: 132–135.

Malik

Bruner

Williams-Weese

, et al. Presence of anti-La autoantibody is associated with a lower risk of nephritis and seizures in lupus patients. Lupus 2007; 16: 863–866.

Reichlin

Mattioli

. Correlation of a Precipitin Reaction to an RNA-Protein antigen and a low prevalence of nephritis in patients with systemic lupus erythematosus. N Engl J Med 1972; 286: 908–911.

10.

Shahin

Hamid

, et al. Cardiac involvement in patients with systemic lupus erythematosus and correlation of valvular lesions with anti-Ro/SS-A and anti-La/SS-B antibody levels. Mod Rheumatol 2004; 14: 117–122.

11.

Hochberg

. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.

12.

Rúa-Figueroa

López-Longo

Calvo

, et al. Registro nacional de pacientes con lupus eritematoso sistémico de la Sociedad Española de Reumatología: objetivos y metodología. Reumatol Clínica 2014; 10: 17–24.

13.

Deyo

Cherkin

Ciol

. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 613–619.

14.

Miyakis

Lockshin

Atsumi

, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.

15.

Gladman

Urowitz

Goldsmith

, et al. The reliability of the systemic lupus International Collaborating clinics/American college of rheumatology damage index in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 809–813.

16.

Baer

McAdams DeMarco

Shiboski

, et al. The SSB-positive/SSA-negative antibody profile is not associated with key phenotypic features of Sjögren’s syndrome. Ann Rheum Dis 2015; 74: 1557–1561.

17.

Danda

Sharma

Truong

, et al.

Anti-La positive, anti-Ro negative subset of primary Sjögren’s syndrome: anti-La is a reality but is the disease?

Clin Exp Rheumatol 2017; 35: 438–444.

18.

Silverman

Mamula

Hardin

, et al. Importance of the immune response to the Ro/La particle in the development of congenital heart block and neonatal lupus erythematosus. J Rheumatol 1991; 18: 120–124.

19.

Ristic

Maisch

. Cardiac rhythm and conduction disturbances: what is the role of autoimmune mechanisms? Herz 2000; 25: 181–188.

20.

Reed

Neufing

Jackson

, et al. Different temporal expression of immunodominant Ro60/60 kDa-SSA and La/SSB apotopes. Clin Exp Immunol 2007; 148: 153–160.

21.

Clancy

Neufing

, et al. Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block. J Clin Investig 2006; 116: 2413–2422.

22.

Nicola

Borrelli

Corradi

, et al. Relationship between clinical manifestations and serological profile in patients affected by Systemic Lupus Erythematosus. Front Immunol 2024; 15: 1390642.

23.

Pisetsky

. Antinuclear antibodies in rheumatic disease: a proposal for a function-based classification. Scand J Immunol 2012; 76(3): 223–228.